Obesity and metabolic impairments are widespread in both psychiatric and non-psychiatric populations. To make matters worse, weight gain, hyperlipidemia, and diabetes are common side effects of the pharmaceuticals we use to treat psychiatric illness.
Sanjay J Mathew, MD
Associate Professor of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Staff Physician, Michael E. Debakey VA Medical Center, Houston, TX
Dr. Mathew has disclosed that he has worked as a paid consultant for AstraZeneca, Naurex, Bristol-Myers Squibb, and Roche/Genentech. Dr. Balt has reviewed this interview and found no evidence of bias in this educational activity.
Can a single infusion of ketamine treat depression? Dr Sanjay Mathew explores the buzz around this treatment.
Cary S. Gunther, PhD
Neurologist and psychiatrist in private practice, Voluntary Faculty, New York Presbyterian-Weill Cornell Medical Center
Dr. Gunther has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Patients with dementia and their families may express frustration about the limited number of options for improving cognitive symptoms, but they are not without choices. Here we will review a number of pharmacological treatment options for Alzheimer’s disease (AD) and other major types of dementia.
Dan G. Blazer, PhD, MD
Vice Chair, Department of Psychiatry and Behavioral Sciences, Vice Chair, Academic Development, Duke University
Dr. Blazer has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Duke University’s Dr. Dan Blazer explains special considerations for treating psychiatric disorders in the elderly.
Prediction of suicidal behavior has long been considered more of an art than a science, although the use of clinical and demographic features can help improve risk assessment. An accurate biological test or “biomarker” for suicidality would be valuable, and a recent study takes us one step closer to that goal.
In September, the American Psychiatric Association (APA) released a list of common, but potentially dangerous and inappropriate, uses for antipsychotics.
The FDA has approved vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD). Brintellix is a novel antidepressant thought to work by enhancing serotonergic acitivty as a serotonin (5-HT) reuptake inhibitor and agonist of the 5-HT1A receptor, among other mechanisms.
Scientists have discovered that the brains of mice clean toxins from between cells while they are sleeping. During sleep, the space between brain cells increases by about 60%, allowing the glymphatic system, or the brain’s “plumbing” system, to flush the brain with fluid.